UNSPSC 51101934: Moxipraquine

This classification denotes an antimalarial agent with the molecular formula C24H38N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GP95SEQ1AQ, chemically known as 1-piperazinepropanol, 4-(6-((6-methoxy-8-quinolyl)amino)hexyl)-alpha-methyl- but generally known as moxipraquine, which bears US NIH Compound Identifier 72091. European Medicines Agency schedules Moxipraquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09088MIG.

UNSPSC 51101934 Moxipraquine is a Commodity code that covers specific pharmaceutical products, though recent state and local opportunities show minimal activity directly aligned with this narrow drug classification. The code appears designed for procurement of the antimalarial medication moxipraquine itself, but the solicitations tagged under it in the current market involve broader pharmaceutical supply arrangements — including antibiotic tablets, naloxone, and drug deactivation systems — suggesting either inconsistent code application by issuing bodies or limited standalone demand for moxipraquine as a line item. State and local health departments and county public health agencies are the primary issuing bodies, typically using cooperative purchasing vehicles such as piggyback contracts through established pharmaceutical consortiums like MMCAP to aggregate volume and leverage existing statewide or regional master agreements.

Recent activity shows sporadic rather than consistent procurement pressure. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 (IFB 26-482DPH-PREPD-B-53392, response due September 11, 2026) totaling $2,999,999.11 over 36 months for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets; Seminole County, Florida issued an IFB on June 30, 2026 (IFB 60459723LAS, response due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building. Activity is geographically dispersed across at least Florida and Illinois with no clear concentration, and the gap between the code's nominal scope (moxipraquine) and the pharmaceuticals actually being procured suggests that businesses pursuing this code should verify issuing-body intent at the pre-bid stage rather than assume standard antimalarial demand.